Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee.
Topol EJ, Armstrong P, Van de Werf F, Kleiman N, Lee K, Morris D, Simoons M, Barbash G, White H, Califf RM. Topol EJ, et al. Among authors: white h. J Am Coll Cardiol. 1992 May;19(6):1123-8. doi: 10.1016/0735-1097(92)90312-b. J Am Coll Cardiol. 1992. PMID: 1564212 Free article. Clinical Trial.
The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group.
Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G. Maggioni AP, et al. Among authors: white h. N Engl J Med. 1992 Jul 2;327(1):1-6. doi: 10.1056/NEJM199207023270101. N Engl J Med. 1992. PMID: 1598096 Free article. Clinical Trial.
Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Barbash GI, White HD, Modan M, Van de Werf F. Barbash GI, et al. Among authors: white hd. J Am Coll Cardiol. 1992 Jul;20(1):36-41. doi: 10.1016/0735-1097(92)90134-9. J Am Coll Cardiol. 1992. PMID: 1607536 Free article. Clinical Trial.
Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.
Simes RJ, Topol EJ, Holmes DR Jr, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, et al. Simes RJ, et al. Among authors: white hd. Circulation. 1995 Apr 1;91(7):1923-8. doi: 10.1161/01.cir.91.7.1923. Circulation. 1995. PMID: 7895348 Clinical Trial.
Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Kleiman NS, White HD, Ohman EM, Ross AM, Woodlief LH, Califf RM, Holmes DR Jr, Bates E, Pfisterer M, Vahanian A, et al. Kleiman NS, et al. Among authors: white hd. Circulation. 1994 Dec;90(6):2658-65. doi: 10.1161/01.cir.90.6.2658. Circulation. 1994. PMID: 7994805 Clinical Trial.
3,507 results